New evidence regarding hormone replacement therapies is urgently required. Transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits by Modena, M. G. et al.
Published in: Maturitas (2005), vol.52, iss.1, pp.1-10 
Status: Postprint (Author’s version) 
New evidence regarding hormone replacement therapies is urgently 
required 
Transdermal postmenopausal hormone therapy differs from oral hormone 
therapy in risks and benefits 
Maria Grazia Modena, Piero Sismondi, Alfred O. Mueck, Frédérique Kuttenn, Bruno de Lignières, Johan 
Verhaeghe, Jean Michel Foidart, Anne Caufriez, Andrea Riccardo Genazzani 
The TREAT1 Collaborative Study Group 
University of Modena and Reggio Emilia, Institute of Cardiology, Modena, Italy 
Abstract: Controversies about the safety of different postmenopausal hormone therapies (HTs) started 30 years 
ago and reached a peak in 2003 after the publication of the results from the Women Health Initiative (WHI) trial 
and the Million Women Study (MWS) [Writing group for the women's health initiative investigations. Risks and 
benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-33; Million women 
study collaborators. Breast cancer and hormone-replacement therapy in the million women study. Lancet 
2003;362:419-27]. The single HT formulation used in the WHI trial for non hysterectomized women—an 
association of oral conjugated equine estrogens (CEE-0.625 mg/day) and a synthetic progestin, 
medroxyprogesterone acetate (MPA-2.5 mg/day)—increases the risks of venous thromboembolism, 
cardiovascular disease, stroke and breast cancer. The MWS, an observational study, showed an increased breast 
cancer risk in users of estrogens combined with either medroxyprogesterone acetate (MPA), norethisterone, or 
norgestrel. It is unclear and questionable to what extent these results might be extrapolated to other HRT 
regimens, that differ in their doses, compositions and administration routes, and that were not assessed in the 
WHI trial and the MWS. Significant results were achieved with the publication of the WHI estrogen-only arm 
study [Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal 
women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-
1712] in which hormone therapy was reserved to women who had carried out hysterectomy. What emerged from 
this study will allow us to have some important argument to develop. 
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1.  Low dose, short duration? 
The EMEA has recommended to use HRT in the "lowest effective dose during the shortest period of time 
whatever the formulation" [4]. This strategy, the simplest recommendation to lower the risks potentially 
extended to the use of any HTs, seems to be endowed with common sense, but is unlikely to significantly 
improve the safety of already tested HTs within the frame of doses and durations of HT prescribed in clinical 
practice [5]. Although there is not a universal accepted definition, we refer to "low-dose estrogen" speaking 
about the administration of 1 mg/day of estradiol, 0.312mg/day of equine conjugated estrogen per os, a dose of 
0.025 mg/day of estradiol patch or a dose of 0.75 mg/day of estradiol gel transdermally administered. 
The combined analysis of the results of four available randomized trials [HERS [6-8], EVTET [9], WEST [10] 
and WHI [1]] concludes that the tested HTs increased the risk of cardiovascular event as early as the first months 
of use, regardless of parameters such as age (although the data available on young, healthy, postmenopausal 
women starting HT are missing), personal medical history, and ethnic origin, [11]. This analysis concluded, 
moreover, that there was a similar risk for all the estrogens administered orally, CEE or 17β-estradiol, including 
the use of estradiol alone, without associated progestin, at the lower dose of 1 mg/day [10,11]. Hence, it would 
seem that use of these HT formulations even at a low dose and during a short duration is not proven to be safe. 
Similarly, available studies show no dose/effect relationship between different HTs [2,12] and the risk of breast 
cancer. The risk of breast cancer may start to rise as soon as the first months of use, but the higher incidence may 
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be attribuable to the fact that women under HT undergo more scrupulous screening for breast cancer, thus 
increasing the probability of detecting malignancies [13]. 
2.  Age dependence of estrogen-mediated cardiovascular risk 
Recent WHI estrogen-only arm study [3] has put clearly in evidence that the reduction of the risk mediated from 
estrogens depends essentially from the age in which women begin to be treated. In this study, in fact, for the age 
group <60 years, the risk of acute myocardial infarction was significantly reduced from 44%, and the risk for 
stroke was not increased. This suggests that a "window of opportunity" exists whereby an early initiation with 
estrogen-only therapy may cause lower cardiovascular risk. For women >59 years, no benefit was observed in 
terms of the risk for coronary heart disease, and the risk of stroke was increased (as for the combined HRT). This 
data emphasizes the great importance of the receptor-mediated effects of estrogens. It is reasonable, in fact, that 
the hormones that were assumed in more juvenile age have both a direct and an indirect effect, this last mediated 
from the vascular receptor. This is the reason why they keep on protecting the vessel in a continuum with the 
fertile period. When the estrogens are administered far after the onset of the menopause, they have only a partial, 
direct effect. The receptor-mediated effect lacks, since the estrogen receptors tend to diminish in number with 
aging. From this point of view, the above cited trials (HERS and WEST) dealt with old populations, not taking in 
any consideration this important physiopathological element. 
3. Routes of administration of estradiol, and cardiovascular risk markers 
A clinically more relevant difference in cardiovascular risk associated with HRT use may be related to the mode 
of treatment, i.e. transdermal (gels or patches) versus oral treatments. The administration of 17β-estradiol 
transdermally (gels or patches), as opposed to orally has a significantly different effect on the immediate markers 
of cardiovascular risk factors. 
For the past 30 years, two conflicting theories have developed on the best way of obtaining cardiovascular 
benefits by administering estrogens to postmenopausal women. 
Up until 2003, the majority of investigators believed that these vascular benefits were specifically linked to the 
pharmacological effects on the HDL and LDL-cholesterol levels provoked by the first pass effect of estrogens in 
the liver. This can only be achieved by oral administration [14,15]. The known secondary effects of this method 
of administration, such as increased triglycerides or haemostasis modifications [16,17], were considered to be 
clinically irrelevant for the vast majority of investigators. The possible association of synthetic progestin was 
expected to have only a minor effect on lipid modifications which remained globally favourable, although the 
co-prescription of MPA, instead of progesterone, significantly reduced the apparent advantages in the PEPI 
randomised study [18]. In USA, since the 1960s, some 90% of HTs prescribed for menopausal women were in 
fact oral administration of a pharmacological estrogen therapy [15] and the results of HERS, WEST and WHI 
were largely unexpected [19,20]. 
In some European countries, since the 1970s, the non-oral administration of an estradiol replacement was 
recommended [21,22]. For the opponents of oral estrogen therapy, the pharmacological accumulation of 
estrogens in the liver induces metabolic modifications comparable to those during pregnancy [22,23]. These 
modifications are very different from those produced by lipid-lowering medicines and are, for the main part, 
unfavourable for menopausal women. These include increased triglycerides, linked to a decrease in the size of 
LDL particles, higher levels of C-reactive protein, and activation of coagulation [21-28]. There is a danger 
therefore, that this pharmacological method of administration, reduces—and not increases-the anti-atherogenic 
effects of estradiol, and therefore increases the risk of venous and arterial thromboembolism. According to this 
hypothesis, the main source of hormone dependent cardio-vascular benefits is not the hepatocyte but the arterial 
endothelium which is estradiol dependent in women [29-35]. 
The choice of the progestin could therefore be important, not so much for the control of the hepatic metabolism 
of cholesterol but for the progestin-estradiol agonistic or antagonistic effects on endothelial function that are also 
progesterone-dependent [36-42]. 
Randomised comparative studies have consistently confirmed the superiority of transdermal estradiol 
replacement to oral formulations on the main intermediates risk markers (triglycerides, size of LDL particles, 
coagulation, C-reactive-protein) (Table 1). This provides a plausible argument in favour of a real difference in 
the benefit/risk ratio between the two routes of administration [24-28,43-46]. 
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One small randomised (PHASE) study failed to demonstrate a potential safety improvement with the use of 
transdermal estradiol [47]. This study recruited 255 postmenopausal women with angiographically-proven 
ischaemic heart disease. Those women were randomly assigned to no treatment (n= 121) or transdermal patches 
delivering either estradiol alone (n = 58) or estradiol + norethisterone (n = 76). After an average of 31 months, 
the CHD event rate for the HT group was 15.6% compared with 12.6% in the control group. Per-protocol 
analysis based on only 81 HT women showed a non-significant increase in the event rate ratio for HT group 
compared with control group (1.49; 95% confidence interval: 0.93-2.36; p = 0.11). However, this study had 
important limitations including the small sample size and high dropout rate (40% in the HT arm). Another 
problem was related to the choice of the transdermal patches delivered by a pharmaceutical company which is no 
longer commercially active (Ethical Pharmaceutical, Ely, UK) and with uncertain pharmacokinetic 
characteristics. 
Table 1: Transdermal estradiol (E2) replacement and oral formulations on the main intermediates risk markers 
of CHD in comparative randomized trials 
 
Last but not least, none of the CHD secondary prevention trials have shown up to now any role of oral estrogen 
administration in reducing recurrent events. This provides the whole rationale behind the fact that oral estrogens 
do not improve the function of diseased vessels, and a large amount of available evidence shows that they indeed 
do not [48]. 
3.1. Venous thromboembolism 
Oral estrogen therapy activates blood coagulation [16,17,24,26] and increases the risk of venous 
thromboembolism (VTE) in postmenopausal women [1,7,9,15]. Transdermal estrogen has little or no effect on 
haemostasis [24,26,49], but clinical data evaluating its effect on the thrombotic process are scarce. A multicentre 
hospital-based case-control study of postmenopausal women conducted in France during 1999-2002 [50], 
recruited 155 consecutive cases with a first documented episode of idiopathic VTE (92 with pulmonary 
embolisms and 63 with deep venous thrombosis), and 381 controls matched for centre, age, and time of 
recruitment. Overall, 32 (21%) cases and 27 (7%) controls were current users of oral estrogens, whereas 30 
(19%) cases and 93 (24%) controls were current users of transdermal estradiol. After adjustment for potential 
confounding variables, the odds ratio for VTE in current users of oral and transdermal estrogens compared with 
non-users was 3.5 (95% CI: 1.8-6.8) and 0.9 (0.5-1.6), respectively. Estimated risk for VTE in current users of 
oral compared with transdermal estrogen users was 4.0 (1.9-8.3). Oral estrogen therapy is associated with risk of 
VTE in postmenopausal women whereas transdermal estradiol replacement is not. These data provide 
epidemiological evidence that transdermal ERT may be safer than oral ERT with respect to thrombotic risk. 
Biological evidence supports the difference in the risk of VTE between oral and transdermal routes of 
administration. Studies of ET and haemostatic variables are scarce but randomised trials have shown that oral ET 
increased plasma level of prothrombin fragment F1 +2, which is a marker for in vivo thrombin generation and a 
predictor of VTE risk [49]. Two trials provided evidence that oral, but not transdermal, ET raised fragment F1+2 
levels [26,43]. A lower antithrombin activity has also been reported in users of oral ERT compared with users of 
transdermal ERT [51]. Thus, oral ERT may impair the balance between procoagulant factors and antithrombotic 
mechanisms, whereas transdermal ET appears to have little or no effect on haemostasis. 
Activated protein C (APC) resistance has recently emerged as a risk factor for VTE [52,53]. APC resistance has 
been demonstrated in women using oral contraceptive [54] but also in those using oral ET [55]. However, two 
randomised trials recently showed that these results did not apply to users of transdermal ET [56,57]. Taken 
together, these findings provide a plausible biological mechanism for the increased risk of VTE among users of 
oral ET and they add to the current evidence that transdermal ET is not involved in the thrombotic process. 
A meta-analysis of the main findings from randomised trials on the long-term effects of ET showed that 
pulmonary embolism accounted for about one third of excess incidence of potentially fatal events in healthy 
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postmenopausal women using ET over 5-year period [11]. Therefore, use of transdermal ERT may substantially 
improve the benefit-risk profile among ERT users. This is even more relevant in the light of the announced 
results of the CEE-only arm of the WHI, that report the presence of increased VTE and stroke incidence in 
women receiving oral estrogens that is similar to what was found in the association arm CEE + MPA, confirming 
the indication that it is the oral administration of estrogen which is specifically linked to increased VTE risk. The 
clinical relevance of those findings might be even more important for women at high risk for VTE who require 
ET for severe menopausal symptoms. 
3.2. CHD and stroke 
The first randomised trials on cardiovascular prevention resulted in failure to confirm any cardiovascular benefit 
related to oral ET, with a homogeneous trend of the appearance of more frequent, more serious and earlier 
cardiovascular accidents in women taking oral formulations compared to those taking a placebo [1,6-8,11]. 
Although laboratory and animal research conducted on the activity of estrogens of vessels showed that estrogen 
therapy induced an increase in circulating HDL-c and a decrease in LDL-c, the clinical use of ET does not 
translate into a slowing of atherosclerosis progression [58-61]. The most convincing explanation is that a parallel 
increase in HDL-c and triglycerides and parallel decrease in LDL-c and LDL particle size is due to a 
pharmacological effect on liver metabolism which is quite different from the beneficial changes induced by 
normolipemic drugs [23,61]. Although there is a potential for beneficial cardiovascular effect of the endogenous 
estradiol (and progesterone), the oral administration of estrogens causes unwanted side effects instead of the 
expected pharmacological benefits on cholesterol metabolism. These unanimously unwanted side effects include 
a rise in triglycerides, a drop in LDL particle size, an activation of coagulation and an increase in C-reactive 
protein [28,43-46,49-52,56,57]. With the non-oral route of administration, the observed effects are quite different 
with a decrease of triglycerides and LDL and no effect mediated by the liver, but definitive evidence-based data 
showing a clinical significance is lacking. Consequently, non-oral estradiol could be the first choice for 
symptomatic postmenopausal women until new evidence would prove otherwise. 
There is no apparent negative effect of non-oral estradiol replacement in France on CHD where the female 
cardiovascular mortality before the age of 74 is among the lowest in the world. The use of HTs (all types) by 
French postmenopausal women soared at the start of the 1990s reaching, in 1999, more than 5 million 
prescriptions each year with more than 21 million units of HTs (estrogen or estro-progestins) and more than 2 
million users [62]. 
The transdermal formulations represented 56% of HT prescriptions for users between 45 and 54 years of age, 
70% for users between 55 and 64 years and 74% for users between 65 and 74 years. 
The evolution of female mortality by CHD in France is not, overall, related to a clear increase in cardiovascular 
risk due to HT The relative increase in CHD incidence expected in the 55-64 age group did not occur despite a 
rapidly increasing exposure to transdermal formulations of HRT since 1990 [63]. 
For symptomatic postmenopausal women willing to start or continue an HT, non-oral estradiol could be the 
considered for first-line prescription, especially in women at high risk of cardiovascular disease. 
4. Effects of HRTs on breast cancer risk 
Despite the fact that natural progesterone has been proved to have beneficial effects on several major targets 
such as the endometrium, the brain, macrophages, and the arterial wall [36-41], the potential for an increased risk 
in breast cancer linked to the use of some synthetic progestins [1,2,11,64] restricts the prescription of any type of 
progestogens and therefore tends to inflate the rate of hysterectomies in peri and postmenopausal women. 
However, the available evidence of risk for breast cancer is limited to only three synthetic progestins suspected 
for 10 years to be inadequate for the control of estrogen effects in breast [65,66], and better benefits/risks ratios 
with other steroids remain plausible. 
4.1. Effects of estrogens on the breast 
Estrogens are clearly the main hormones to trigger both proliferation of normal breast epithelial cells and 
progression of breast cancer cells [67,68]. One of the prevailing theory concerning the mechanism of estrogen-
induced increase of breast cancer risk postulates that estrogens increase the proliferation of breast cells and 
thereby the number of errors occurring during cell replication, but notwithstanding the large research efforts 
devoted in this area in the last years, this has not been clearly demonstrated, and many experts believe now that 
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estrogens may only act as promoting agents of already existing tumors, being therefore devoid of oncogenic 
power. Other mechanisms may be responsible, i.e. the formation of estradiol and estrone metabolites reacting 
with DNA. Evidence is growing that both mechanisms may be operative in an additive or synergistic fashion. 
It was demonstrated that certain estradiol metabolites have antiproliferative and antiangiogenetic properties 
[69,70]. The distribution of primary reactive estradiol metabolites was investigated in 37 postmenopausal women 
treated either with 2 mg oral or 0.05 mg transdermal estradiol [71]. No significant changes were found with the 
patch. In contrast, under oral estradiol, an almost 10-fold increase was observed, not only in 2α-hydroxyestrone, 
but also in 16α-hydroxyestrone, a D-ring metabolite with high biological activity [72]. Particularly women 
smokers under treatment with oral estradiol produced significantly more 4-hydroxyestradiol, which (via quinone 
formation) can have DNA-toxic effects increasing the risk of developing breast cancer [73]. However, the 
formation of potentially toxic metabolites was avoided if estradiol was used transdermally. 
Before menopause, the main source of estrogens for all target tissues including breast is the cyclic secretion of 
estradiol by ovaries in the systemic circulation. 
After menopause, despite the ovarian estradiol secretion drop, there is only a partial regression of the normal 
breast tissue and breast cancer incidence continues to increase with age that remains the major risk factor for 
cancer. Most breast cancers are diagnosed after the menopause [74] when serum estradiol levels are very low, 
but, even in these circumstances, an important role of this hormone in the development of the disease remains 
pivotal. 
Breast adipose tissue and most breast carcinomas acquire aromatase (metabolising androstenedione to estrone) 
and 17β-hydroxysteroid dehydrogenase type 1 (metabolising estrone to estradiol) activities efficient enough to 
locally synthesize estradiol from androgenic substrates. This pivotal mechanism maintains the growth of 
estrogen-dependent cancers independently of estrogen serum levels [75]. However, during the menopausal 
transition, the main source of estrogen for the breast switches from the premenopausal cyclic serum production 
of estradiol by the ovaries to a postmenopausal in situ continuous synthesis of estrogens from circulating 
androgens, their local aromatisation to estrone, and then, reduction of estrone to estradiol. 
Therefore, the overall risk of again raising serum estradiol or estrone in postmenopausal women is expected to be 
relatively low [76,77]. It concerns mainly women with a lean body weight and symptoms of estrogen 
deprivation, likely to have low aromatase and 17β-hydroxysteroid dehydrogenase type 1 activities. If these 
women use estrogen replacement therapy, their breast cancer risk increases to the level observed in untreated 
postmenopausal women who are slightly overweight and do not experience climacteric symptoms. This risk does 
not appear to be dose-related. The use of an estradiol or estrone replacement therapy does not alter the breast 
cancer risk in women who are slightly overweight, have no symptoms of estrogen deprivation and then are likely 
to have relatively high aromatase and 17β-hydroxysteroid dehydrogenase type 1 activities. The positive 
correlation between BMI and risk of breast cancer in postmenopausal women is clearly linked to the ability of 
adipose tissue to synthesise estradiol continuously [78]. The reanalysis of 51 epidemiologic studies showed that 
estrogen therapy increases the risk of breast cancer only in postmenopausal women with a BMI <25, which is 
consistent with the observed lack of estrogen-dose related effect [75]. This hypothesis should be accepted 
according also with the results of the WHI estrogen-only arm (3). In this last trial, in fact, there was a largely 
surprising significant risk reduction for breast cancer of 33%. This was due to the specific characteristic of the 
selected study population: women were, on average, obese (mean BMI: 30.1 kg/m2; 45% of the population had a 
BMI >45 kg/m2), and It is well known that hormone therapy does not increase breast cancer risk in obese 
women. Currently, the question why breast cancer risk was reduced in the trial remains opened, as also 
concluded by the authors. 
By contrast, breast tenderness is clearly estrogen-dose related [5]. 
4.2.  Estrogen agonist and antagonist effects of progestogens on breast 
Progestogens have different influences on the main estrogen activities in pre- or postmenopausal women, when 
breast is mostly stimulated by cyclic fluctuations in serum estradiol or by continuous in-situ synthesis through 
aromatase and 17β-hydroxysteroid dehydrogenase type 2 activities. 
4.3.  Progestogens in premenopausal women 
The main estrogen antagonist effect of progestogens is primarily linked to their ability to decrease estradiol 
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ovarian production through their anti-gonadotropic effect. A second effect is related to a local impact of 
progesterone and some synthetic progestins able to down-regulate estradiol receptors within normal breast 
epithelial cells [67] and to stimulate 17β-hydroxysteroid dehydrogenase type 2 activity (metabolizing estradiol to 
estrone) [79,80]. Applying a natural progesterone gel on breast skin decreases the mitotic activity stimulated by 
estradiol [81,82]. Also, a combination of topical progesterone and synthetic oral progestins has been successfully 
used to treat mastodynia and to decrease the risk of breast cancer in women with benign breast diseases [83]. 
In women using oral contraceptives both the anti-gonadotropic effect and the 17β-hydroxysteroid dehydrogenase 
type 2 stimulation of the progestin are ineffective on co-administered exogenous ethinyl-estradiol, and the 
incidence of benign diseases of the breast is related to the individual metabolism of both steroids with a tendency 
to decrease with lower dose of estradiol and higher dose of progestin [84]. However, some synthetic progestins 
with androgenic properties may become mostly estrogen agonists in some individuals by directly binding to 
estrogen receptors [65]. 
Oral contraceptives do not seem to have significant influence on breast cancer risk [85], although contraceptives 
containing high doses of ethinyl-estradiol and or potentially androgenic progestins such as norgestrel remain 
suspected to slightly increase the risk [86]. 
4.4.  Progestogens in postmenopausal women 
The anti-gonadotropic effect of progestogens is not useful in postmenopausal women and the use of androgenic 
progestins may upregulate estradiol receptors. Moreover, the effects on 17β-hydroxysteroid dehydrogenase 
activities are quite different from one progestin to one other, and medroxyprogesterone acetate, norethisterone 
and norgestrel have been shown to preferentially stimulate the iso-enzyme 1 metabolizing estrone to estradiol, 
while this is not the case with progesterone [66]. This is specifically worrying when the estrogen is co-
administered by the oral route and induces a striking accumulation of estrone in the breast tissue [87]. The WHI 
and MWS studies reporting alarming results on breast cancer incidence and possibly on mortality have analyzed 
exclusively the effects of these three synthetic progestins [2,64] but other studies on treatments using more 
physiological combinations deliver a better message [88,89]. 
It was demonstrated that equine estrogens have a proliferative action similar to 17β-estradiol and that the 
continuous addition of progestins did not result in any major reduction of proliferative potency [90]. Some 
progestins may even enhance the estrogen-induced proliferation of pre-existing breast cancer cells in vitro, 
particularly when combined with certain equine estrogens. However, in none of the tested circumstances 
progestogens increase the proliferative effect of estradiol, and progesterone has no deleterious effect even at 
pharmacological levels, by contrast with progestins. 
In in vitro studies, natural progesterone down-regulates estradiol receptors and inhibits the cell proliferation 
stimulated by estradiol in normal human breast epithelial cells [67]. Similarly, progesterone arrests human breast 
cancer cells in G-1 phase on the second cycle by up-regulating cyclin dependent kinase inhibitors (p 21-p 27) 
and down regulating cyclin D1 [91,92]. Some studies performed on breast tumor cell lines show a pro-apoptotic 
effect of progesterone [93], reproduced by some non androgenic progestin [94] while another study shows an 
anti-apoptotic effect of medroxyprogesterone acetate (MPA) [95]. Therefore, in vitro studies show dominant 
estradiol antagonist activities from progesterone, decreasing the growth of human normal and malignant breast 
epithelial cells, but also show large discrepancies in the effects of various synthetic progestins. Based on the 
analysis of proliferation markers in surgical biopsies from normal human postmenopausal breast tissue, 
mitogenic activity appears to be higher during HRT which combines oral conjugated equine estrogens with 
medroxyprogesterone acetate [96] than during HRT which combines transdermal estradiol and progesterone 
[97]. In two cohorts of long-term users of this last combination, no increase in breast cancer incidence has been 
detected [88,98]. 
In conclusion, it is misleading to put all progestogens in the same bag, irrespective of their chemical structure 
and specifically of their ability to stimulate estradiol synthesis and activities in the postmenopausal breast. Also, 
their effect may vary whether it is estrone or estradiol that is mainly accumulated in the breast tissue. The 
hypothesis of progesterone and some progesterone-like progestins decreasing the proliferative effect of estradiol 
in the postmenopausal breast remains highly plausible and should be, until the coming of new evidences, the first 
choice for symptomatic postmenopausal women. 
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